Metraipolis › archive › dc_0eb2cee563b0

Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies — Europe PMC PMID:41568384

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41568384
DOI
10.3389/fonc.2025.1591759
License (as archived)
solo-consultazione
Archived
2026-11-07T00:43:25.369Z
SHA-256 of the archived text
09e9bf1acd235d2d3fe5deb6a7423353cee3d6e66d3b02fc6b087d94e5112ce6
Stable URL of this page
https://metraipolis.com/documento/dc_0eb2cee563b0

How to cite

Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies — Europe PMC PMID:41568384 — Europe PMC (en), https://europepmc.org/article/MED/41568384 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0eb2cee563b0 (Metraipolis archive dc_0eb2cee563b0, sha256 09e9bf1acd235d2d3fe5deb6a7423353cee3d6e66d3b02fc6b087d94e5112ce6)
BibTeX
@misc{dc0eb2cee563b0,
  title = {Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies — Europe PMC PMID:41568384},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41568384},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0eb2cee563b0; sha256 09e9bf1acd235d2d3fe5deb6a7423353cee3d6e66d3b02fc6b087d94e5112ce6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41568384. Agents can read the archived copy with the MCP tool read_document.